New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting ...Middle East

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A...

Hence then, the article about new novartis data show early addition of twice yearly leqvio inclisiran following maximally tolerated statin therapy significantly reduces ldl c in ascvd patients in real world setting was published today ( Saturday 06/04/2024 - 11:20 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting )

Also on site :

• Firefighters rush to Morrisons convenience store in Oswestry after report of fire
• Today's Famous Celebrity Birthdays for March 22, 2026: Reese Witherspoon, William Shatner
• Iranian Revolutionary Guard: 200 Killed and Wounded Among Zionist Enemy in 73rd Wave